Page last updated: 2024-08-24

pivalyloxymethyl butyrate and Benign Neoplasms

pivalyloxymethyl butyrate has been researched along with Benign Neoplasms in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Britten, CD; Burton, S; Eckhardt, SG; Felton, SA; Goetz, A; Hammond, LA; Patnaik, A; Rowinsky, EK; Siu, LL; Valone, FH; Villalona, MA	1
Batova, A; Diccianni, MB; Nudelman, A; Rephaeli, A; Shao, LE; Tanaka, T; Yu, AL; Yu, J	1
Cutts, SM; Nudelman, A; Phillips, DR; Rephaeli, A; Swift, LP	1
Hobdy, E; Murren, J	1

Reviews

2 review(s) available for pivalyloxymethyl butyrate and Benign Neoplasms

Article	Year
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Butyrates; Cell Differentiation; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs; Safety	2002
AN-9 (Titan). Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:6 Topics: Animals; Antineoplastic Agents; Butyrates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drugs, Investigational; Humans; Neoplasms	2004

Article

Year

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:7

Topics: Adult; Aged; Antineoplastic Agents; Butyrates; Cell Differentiation; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs; Safety

2002

AN-9 (Titan).

Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:6

Topics: Animals; Antineoplastic Agents; Butyrates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drugs, Investigational; Humans; Neoplasms

2004

Trials

1 trial(s) available for pivalyloxymethyl butyrate and Benign Neoplasms

Article	Year
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Butyrates; Cell Differentiation; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs; Safety	2002

Article

Year

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:7

Topics: Adult; Aged; Antineoplastic Agents; Butyrates; Cell Differentiation; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs; Safety

2002

Other Studies

2 other study(ies) available for pivalyloxymethyl butyrate and Benign Neoplasms

Article	Year
The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood, 2002, Nov-01, Volume: 100, Issue:9 Topics: Acetylation; Acute Disease; Apoptosis; Butyrates; Cell Division; Child; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Genes, MDR; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Histones; HL-60 Cells; Humans; Infant; Inhibitory Concentration 50; Leukemia; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Processing, Post-Translational; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay	2002
Sequence specificity of adriamycin-DNA adducts in human tumor cells. Molecular cancer therapeutics, 2003, Volume: 2, Issue:7 Topics: Antibiotics, Antineoplastic; Base Sequence; Butyrates; DNA; DNA Adducts; Doxorubicin; Formaldehyde; Humans; Molecular Sequence Data; Neoplasms; Tumor Cells, Cultured	2003

Article

Year

The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.

Blood, 2002, Nov-01, Volume: 100, Issue:9

Topics: Acetylation; Acute Disease; Apoptosis; Butyrates; Cell Division; Child; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Genes, MDR; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Histones; HL-60 Cells; Humans; Infant; Inhibitory Concentration 50; Leukemia; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Processing, Post-Translational; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay

2002

Sequence specificity of adriamycin-DNA adducts in human tumor cells.

Molecular cancer therapeutics, 2003, Volume: 2, Issue:7

Topics: Antibiotics, Antineoplastic; Base Sequence; Butyrates; DNA; DNA Adducts; Doxorubicin; Formaldehyde; Humans; Molecular Sequence Data; Neoplasms; Tumor Cells, Cultured

2003